Literature DB >> 17437666

Ibandronate injections in postmenopausal women with osteoporosis.

Gim Gee Teng, Nivedita M Patkar, Kenneth G Saag.   

Abstract

Entities:  

Year:  2007        PMID： 17437666

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  7 in total

1.  Denosumab in postmenopausal women with low bone mineral density.

Authors:  Julie Schwartzman; Yusuf Yazici
Journal:  N Engl J Med       Date:  2006-06-01       Impact factor: 91.245

2.  Compliance with osteoporosis therapy is the weakest link.

Authors:  Juliet E Compston; Ego Seeman
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

3.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

Review 4.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

5.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

6.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.

Authors:  Y Y Kong; H Yoshida; I Sarosi; H L Tan; E Timms; C Capparelli; S Morony; A J Oliveira-dos-Santos; G Van; A Itie; W Khoo; A Wakeham; C R Dunstan; D L Lacey; T W Mak; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-01-28       Impact factor: 49.962

7.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.